Pembrolizumab plus chemo as firstline therapy for NSCLC

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients

Firstline pembrolizumab plus chemo improves NSCLC outcomes

KRAS in the clinic and conference

A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)

Thousands of melanoma patients in Europe have no access to new drugs

Phase I results of a novel FGFR inhibitor

Firstline pembrolizumab for metastatic urothelial cancer

Ribociclib improves progression-free survival in advanced breast cancer

Niraparib significantly improves outcomes for ovarian cancer patients

Ipilimumab as adjuvant therapy improves OS in high risk melanoma